🧵1/ 🙏🏾🙏🏾Thank you patients, families, trial staff and investigators for participating in @TROGfightcancer
15.03 FASTRACK II! This trial recruited n=70 across 8 sites in 🇦🇺 and 🇳🇱 #ASTRO23! #radonc #kcsm #radiotherapy @ANZUPtrials @KidneyCancer 🧵2/ SABR is a novel treatment for primary #kidneycancer which is non-invasive and has fewer technical limitations than thermal ablation. We tested SABR in a 🦘&🌷phase II trial for primary RCC that was inoperable or high-risk for surgery. The benchmark was 90% control at 1-year.

1/ 🙏 patients, investigators and funders for
@TROGfightcancer 13.01 SAFRON II trial at #ESTRO21. n=90 pts with 133 pulmonary oligometastases, across 13 centers in 🇳🇿+🇦🇺. Median F/U = 3 years, randomization for single (SF) 28Gy vs 48Gy in 4fx (MF). #radonc #LCSM @PeterMacCC 2/ No difference in SF vs MF. Both were safe (G3+ AEs were 5% MF v 3% SF), and effective - 2yr OS 85% MF v 88% SF (p=0.44), LC 83% MF v 73% SF (p=0.13). No diff. in DFS (median 13.2 MF v 14.3 SF, p=0.99). Mean time to systemic treatment ~29mo. SABR did not impact QoL measures